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Abstract
Pancreatic cancer is one of the deadliest cancers with poor survival rates and limited therapeutic options. To improve the understanding of this disease's biology, a prerequisite for the generation of novel therapeutics, new platforms for rapid and efficient genetic and therapeutic screening are needed. Therefore, a combined in vitro/in vivo hybrid shRNA-assay was developed using isolated murine primary pancreatic ductal cells (PDCs), in which oncogenic Kras alone was not sufficient to induce tumor growth. Implications: The combinatory in vitro/in vivo approach described in this study allows for rapid and efficient identification of genes involved in carcinogenesis and opens new avenues for the development of therapeutic strategies to improve cancer treatment.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related deaths in the US. The five-year survival rate of all patients suffering from PDAC is 6%, and incidence almost equals mortality rate, underscoring the aggressive behavior of this tumor (1) . Most patients suffering from PDAC already present with metastasis, causing the majority of pancreatic cancer associated deaths (2) . Although several broad based approaches have been undertaken to shed light on the genetics and biology of pancreatic cancer, only few essential driver mutations have been identified so far (3, 4) . One of the most common genetic perturbations in pancreatic cancer is an activating mutation of oncogenic Kras, which can be found in more than 90% of PDAC and is thought to represent an initiating event (5) . However, single activation of Kras in mice results in pancreatic intraepithelial neoplasia (PanIN), but shows only infrequent development of invasive PDAC (6) . Thus, additional genetic events are required for the development of invasive PDAC, including loss of the cell cycle regulator p16
Ink4a
(part of the Cdkn2a-locus), and of the tumor suppressor genes Trp53 and/or Smad4 (7). Identification of additional genes involved in tumorigenesis will broaden our understanding of pancreatic cancer biology and eventually lead the way to more effective treatments. The standard approach for investigating candidate cancer genes requires the generation of transgenic and knockout mice that harbor germline alterations in the gene of interest. Although these strains are invaluable tools in the field of cancer research, their generation, maintenance and analysis can be costly and time consuming. Moreover, many data obtained with these models rely on manipulation of cancer genes during embryogenesis, and thus, do not reflect somatic mutations occurring during an individual's life span.
To obviate these obstacles, we developed an approach in which we combined the ease of in vitro genetic manipulation and the power of in vivo pancreatic cancer studies. In this model, we took advantage of the well-established primary pancreatic ductal cell culture (PDCs) (8, 9) . Isolation of PDCs from mice that harbor the lox-stop-lox-Kras 
Material and Methods
Isolation of Pancreatic ductal cells
Primary pancreatic ductal cells (PDCs) were isolated from mice carrying the genotype ROSA26Cre-ER
T2
;Lox-Stop-Lox-Kras
G12D
(termed Kras-PDCs thereafter) and maintained essentially as described (10) . Early passage cells
were treated with 4OH-tamoxifen 200 nM (Sigma) or vehicle for 10 days.
Western Blot Analysis
PDCs were collected from collagen by digestion with collagenase type 2 
RAS activation assay
Detection of activated KRAS was performed essentially as described using a Raf-RBD-pulldown assay (Cytoskeleton) (11) . Transfer to PVDF membranes and visualization was conducted as mentioned above using an antibody against KRAS (Merck-Millipore, 1:1000).
Quantitative Real-Time PCR
Total RNA was extracted using the RNeasy kit (Qiagen). Synthesis of cDNA using random hexamers and MMLV-based reverse transcriptase (Life Technologies) was achieved as previously described (12) . Quantitative analysis was carried out on StepONEplus real-time PCR system (Applied Biosystems, Life Technologies) and the amount of target gene was normalized to the endogenous reference Ppia (Cyclophilin A) (13) .
Murine primers were designed to be intron spanning. The following primers were Kras-PDCs were transduced with lentivral constructs as described with only minor modifications (14) . Briefly, 4OH-tamoxifen-treated Kras-PDCs were placed in wells of a six-well plate at a cell number of 3x10 5 cells/well and allowed to adhere on plastic over night. Next day, cells were transduced with viral supernatant containing ploybrene 4 µg/ml (Sigma). Twenty-four hours later PDCs were placed back onto collagen coated wells and were allowed to adhere for another 24 h. Upon complete attachment, cells were selected in the presence of puromycin 8 µg/ml for ten days (termed Kras-shRNA-PDCs hereafter). 
Statistical Analysis
Statistics were performed using graph pad prism. For expression analysis, student's t-test was used. To analyze survival after orthtopic implantation of KrasshRNA-PDCs, Log-Rank (Mantle-Cox) analysis was applied.
Results
Development of an in vitro Kras activation method
To obtain a strictly genetically defined model without contaminating stromal cells we decided to isolate a purely ductal cell population from the pancreas for further in vitro manipulation. Since Kras is mutated in over 90% of PDAC cases, we chose in vitro activation of LSL-Kras 
Loss of Trp53 leads to tumor growth
To address the question whether increased tumor growth is specific to the loss of reaction ( Figure 5 A and B) . Macrosopic liver metastasis occurred in three out of five tumor bearing animals and was confirmed by histology ( Figure S2 ).
shRNA mediated gene silencing results in decreased survival
In total, five out of six animals receiving Kras-shRNAp16
Ink4a
-PDCs or KrasshRNATrp53-PDCs developed tumors. These animals display a significantly shorter survival when compared to animals that received Kras-shRNAControl.
However there was no difference between animals implanted with KrasshRNAp16
Ink4a
-PDCs or Kras-shRNATrp53-PDCs ( Figure S3 ).
Discussion
The data presented here demonstrate a stepwise manipulation of adult pancreatic ductal cells to model PDAC in vivo. First, we report isolation of an already well-defined pancreatic cell population that can be genetically altered by (24)), and we do not know about any report of development of PDAC upon pancreas specific Trp53-deletion. Thus, our model more closely resembles a truly sequential second-hit carcinogenesis as initially proposed by Knudson in 1971 (25) .
In contrast to the human disease and most genetically engineered mouse models of pancreatic cancer, the tumors described in this study lack the classical stromal component and show a more dedifferentiated phenotype. This observation may be due to various reasons. First, we injected ductal cells that have undergone genetic maipulation. However, the induction of a stromal cell response is known to take place early in PDAC development, so that this critical phase might be missed in our model (26) . Second, NOD scid gamma mice used in this study are depleted for B-and T-cells, which are also believed to play an important role during the generation of a stromal response (27) . Third, injection of a cell suspension might not reflect the hypoxic conditions naturally occurring in a solid tumor, thereby reducing levels of secreted factors that usually foster development of a stromal reaction (28) . Intriguingly, tumors described in this study closely resemble those seen in mouse models that a priori lack the stromal compartment (29, 30) . However, we argue that orthotopic implantation is preferred over subcutaneous tumor xenograft models as the latter completely lack tumor cell interaction with neighboring cells at the naturally occurring site of origin of PDAC. This might not only be important in tumor initiation processes but also during the course of metastasis.
Because p16
Ink4a
and Trp53 act non-redundantly through either the control of cell cycle regulation or DNA damage repair mechanisms (31), we argue that our model will be an expandable and powerful tool to screen for new tumor suppressor genes and will broaden our understanding of cancer biology.
Moreover, the principle of stepwise in vitro acquisition of genetic hits in primary pancreatic ductal cells may be transferrable to other techniques of gene modulation, including genome editing using CRIPSR/Cas9, as it has already been described for liver cancer (32) . 
